Recombinant Human PD-L1/B7-H1 His-tag Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Mature human B7-H1 consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic domain (2). Within the ECD, human B7-H1 shares 73% and 74% aa sequence identity with mouse and rat B7-H1, respectively. Alternative splicing generates additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (3). B7-H1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (4-7), keratinocytes (8, 9), enothelial and intestinal epithelial cells (8, 10), as well as a variety of carcinomas and melanoma (11, 12). B7-H1 binds to T cell B7-1/CD80 and PD-1 (7, 8, 12-15). It suppresses T cell activation and proliferation (5, 8, 14, 16) and induces the apoptosis of activated T cells (11). It plays a role in the development of immune tolerance by promoting T cell anergy (7, 14) and enhancing regulatory T cell development (16). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (5, 10) and inhibits the development of Th17 cells (16). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (6, 9, 12, 15).

We have publications tested in 1 confirmed species: Human.

We have publications tested in 2 applications: Bioassay, Surface Plasmon Resonance.

Showing Publications 1 - 7 of 7.

Publications using 9049-B7	Applications	Species
T Phetphoung, A Malla, K Rattanapis, N Pisuttinus, N Damrongyot, K Joyjamras, P Chanvorach, T Phakham, T Wongtangpr, R Strasser, C Chaotham, W Phoolcharo Expression of plant-produced anti-PD-L1 antibody with anoikis sensitizing activity in human lung cancer cells via., suppression on epithelial-mesenchymal transition PLoS ONE, 2022-11-11;17(11):e0274737. 2022-11-11 [PMID: 36367857] (Bioassay, Human)	Bioassay	Human
ZH Wu, N Li, ZZ Gao, G Chen, L Nie, YQ Zhou, MZ Jiang, Y Chen, J Chen, XF Mei, F Hu, HB Wang Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-beta for Anticancer Immunotherapy Cancers, 2022-10-10;14(19):. 2022-10-10 [PMID: 36230887] (Bioassay, Human)	Bioassay	Human
R Le Biannic, R Magnez, F Klupsch, N Leleu-Chav, B Thiroux, M Tardy, H El Bouazza, X Dezitter, N Renault, G Vergoten, C Bailly, B Quesnel, X Thuru, R Millet Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction European Journal of Medicinal Chemistry, 2022-04-04;236(0):114343. 2022-04-04 [PMID: 35429911] (Bioassay, Human)	Bioassay	Human
L Sun, Y Wang, X Wang, A Navarro-Co, S Ilyas, N Jalan-Sakr, C Gan, X Tu, Y Shi, K Tu, Q Liu, Z Lou, H Dong, AH Sharpe, VH Shah, N Kang PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-beta receptor I versus II Cell Reports, 2022-02-08;38(6):110349. 2022-02-08 [PMID: 35139382] (Bioassay, Human)	Bioassay	Human
C Geuijen, P Tacken, LC Wang, R Klooster, PF van Loo, J Zhou, A Mondal, YB Liu, A Kramer, T Condamine, A Volgina, LJA Hendriks, H van der Ma, E Rovers, S Engels, F Fransen, R den Blanke, V Zondag-van, A Basmeleh, W Bartelink, A Kulkarni, W Marissen, CY Huang, L Hall, S Harvey, S Kim, M Martinez, S O'Brien, E Moon, S Albelda, C Kanellopou, S Stewart, H Nastri, ABH Bakker, P Scherle, T Logtenberg, G Hollis, J de Kruif, R Huber, PA Mayes, M Throsby A human CD137�PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade Nature Communications, 2021-07-21;12(1):4445. 2021-07-21 [PMID: 34290245] (Surface Plasmon Resonance, Human)	Surface Plasmon Resonance	Human
JJ Park, EP Thi, VH Carpio, Y Bi, AG Cole, BD Dorsey, K Fan, T Harasym, CL Iott, S Kadhim, JH Kim, ACH Lee, D Nguyen, BS Paratala, R Qiu, A White, D Lakshminar, C Leo, RK Suto, R Rijnbrand, S Tang, MJ Sofia, CB Moore Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1 Nature Communications, 2021-02-22;12(1):1222. 2021-02-22 [PMID: 33619272] (Bioassay, Human)	Bioassay	Human
Samit Chatterjee Rapid PD-L1 detection in tumors with PET using a highly specific peptide Biochem. Biophys. Res. Commun, 2016-12-24;0(0):. 2016-12-24 [PMID: 28025143] (Bioassay)	Bioassay

Array 9049-B7

• PD-L1 Antibodies
• PD-L1 Antibody Pairs
• PD-L1 ELISA Kit
• PD-L1 Lysate
• PD-L1 Proteins
• PD-L1 Proteins and Enzymes
• PD-L1 ELISAs